Pulmonary Arterial Hypertension: Market Insights, Epidemiology and Market Forecast to 2027

  • ID: 4433434
  • Drug Pipelines
  • Region: Global
  • 98 Pages
  • DelveInsight
1 of 5
Thorough Assessment of Competitors, Market, Current Trends & Treatments Along With Upcoming Treatments

Pulmonary Arterial Hypertension - Market Insights, Epidemiology and Market Forecast - 2027 report provides an overview of the disease and in depth research related to Pulmonary Arterial Hypertension for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2027. Pulmonary Arterial Hypertension (PAH), [WHO Class I] is a rare, chronic, and progressive form of Pulmonary Hypertension, which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from right side of heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.

Prevalence of PAH varies according to the geographical distribution, environmental factors, sex, age and socioeconomic factors. Despite the advancement and improvement in treatment owing to the unmet need of Pulmonary Arterial Hypertension the number of patients suffering from this rare disease is constantly increasing over the years. Amongst the major sub-types of PAH i.e., Idiopathic PAH, heritable PAH, and disease associated PAH, atleast more than 30% prevalent population suffers from idiopathic PAH. Unlike the previous studies, which underestimated the prevalence of PAH, the latest research findings have exhibited significant increment in the patient population. It was estimated that United States has higher prevalence of PAH as compared to EU5 and Japan. Among the EU5 countries, Germany accounts for the highest prevalence of PAH whereas Spain accounts for the lowest prevalence of PAH.

Our estimation suggests that the total prevalent cases of PAH shall increase with the compound annual growth rate (CAGR) of 1.37% from 2013 to 2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Pulmonary Arterial Hypertension. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Pulmonary Arterial Hypertension for 7 major markets.

According to research, the Global Market Size of PAH was found to be USD 5.13 Billion in 2016. The report will help in enhanced understanding of the Pulmonary Arterial Hypertension market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Pulmonary Arterial Hypertension market, as well as treatment algorithm, current treatments & advancements are included. The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Pulmonary Arterial Hypertension, providing an in-depth analysis of emerging therapies which will create an impact through their launch.

Key Coverage:

  • Understanding historical and forecasted epidemiological data for Pulmonary Arterial Hypertension covering 7MM from 2015-2027
  • Segment level epidemiology and market split for Pulmonary Arterial Hypertension
  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Pulmonary Arterial Hypertension
  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2027 and detailed historical and forecasted Pulmonary Arterial Hypertension market trends
  • Thorough market distribution based on market share for Pulmonary Arterial Hypertension

Reasons to Buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market
  • To understand the future market competition in the Pulmonary Arterial Hypertension market and an insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
READ MORE
Note: Product cover images may vary from those shown
2 of 5

1. Report Introduction

2. Pulmonary Arterial Hypertension Market Overview at a Glance
2.1. Global Market Share Distribution of Pulmonary Arterial Hypertension in 2016
2.2. Global Market Share Distribution of Pulmonary Arterial Hypertension in 2027

3. Pulmonary Arterial Hypertension (PAH): Overview
3.1. Signs and Symptoms
3.2. Classification of Pulmonary Arterial Hypertension (PAH)
3.3. Functional Classification of PAH
3.4. Etiology
3.5. Risk factors
3.6. Pathophysiology
3.7. Diagnosis
3.8. Treatment

4. Epidemiology and Patient Population
4.1. Key Points
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Pulmonary Arterial Hypertension (PAH) in 7MM
4.3.1. United States
4.3.1.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.1.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.1.3. Gender Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.2. Germany
4.3.2.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.2.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.2.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.3. France
4.3.3.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.3.2. Sub-type Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.3.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.4. Italy
4.3.4.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.4.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.4.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.5. Spain
4.3.5.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.5.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.5.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.6. United Kingdom
4.3.6.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.6.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.6.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4.3.7. Japan
4.3.7.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.7.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
4.3.7.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)

5. Treatment Algorithm
5.1. United States
5.1.1. CHEST Guidelines
5.2. Europe
5.2.1. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

6. Unmet Needs

7. Marketed Products
7.1. Approval and Market Presence
7.2. Company-Wise Marketed Products
7.2.1. United Therapeutics Corporation
7.2.1.1. Comparative Analysis of Marketed Therapies
7.2.1.1.1. Mechanism of action
7.2.1.1.2. Regulatory Milestones
7.2.1.1.3. Safety and efficacy profiles
7.2.1.1.4. Side effects
7.2.1.1.5. Product profile
7.2.2. Actelion Pharmaceuticals Ltd.
7.2.2.1. Comparative Analysis of Marketed Therapies
7.2.2.1.1. Mechanism of action
7.2.2.1.2. Regulatory Milestones
7.2.2.1.3. Safety and efficacy profiles
7.2.2.1.4. Side effects
7.2.2.1.5. Product profile
7.2.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
7.2.3.1. Comparative Analysis of Marketed Therapies
7.2.3.1.1. Mechanism of action
7.2.3.1.2. Regulatory Milestones
7.2.3.1.3. Safety and efficacy profiles
7.2.3.1.4. Side effects
7.2.3.1.5. Product profile
7.2.4. Bayer AG
7.2.4.1. Comparative Analysis of Marketed Therapies
7.2.4.1.1. Mechanism of action
7.2.4.1.2. Regulatory Milestones
7.2.4.1.3. Safety and efficacy profiles
7.2.4.1.4. Side effects
7.2.4.1.5. Product profile
7.2.5. Pfizer
7.2.5.1. Comparative Analysis of Marketed Therapies
7.2.5.1.1. Mechanism of action
7.2.5.1.2. Regulatory Milestones
7.2.5.1.3. Safety and efficacy profiles
7.2.5.1.4. Side effects
7.2.5.1.5. Product profile

8. Emerging Therapies
8.1. Tysuberprost: United Therapeutics Corporation
8.1.1. Regulatory Milestones
8.1.2. Clinical Development
8.1.3. Product Profile
8.1.4. Clinical Pipeline Activity
8.1.4.1. Ongoing Trials Information
8.1.4.2. Clinical Trial by Phase
8.2. Aurora GT: United Therapeutics Corporation
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. Macitentan: Actelion Pharmaceuticals Ltd.
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trial by Phase

9. Pulmonary Arterial Hypertension (PAH) Market Size
9.1. Key Findings
9.2. Global Market Outlook: Pulmonary Arterial Hypertension (PAH)
9.2.1. Assumptions and Forecast Parameters
9.2.2. Global Market Analysis
9.3. Total 7MM Pulmonary Arterial Hypertension (PAH) Market Analysis
9.3.1. Overview of Total Pulmonary Arterial Hypertension (PAH)Market (2016-2027)
9.4. Region-Wise Market Analysis
9.4.1. United States Market Size
9.4.1.1. Assumptions
9.4.1.2. Market Analysis
9.4.1.3. Emerging therapies analysis: Impact on the market
9.4.2. Europe Market Size
9.4.2.1. Assumptions and Forecast Parameters
9.4.2.2. Germany Market Size
9.4.2.2.1. Market Analysis
9.4.2.2.2. Emerging therapies analysis: Impact on the market
9.4.2.3. France Market Size
9.4.2.3.1. Market Analysis
9.4.2.3.2. Emerging therapies analysis: Impact on the market
9.4.2.4. United Kingdom Market Size
9.4.2.4.1. Market Analysis
9.4.2.4.2. Emerging therapies analysis: Impact on the market
9.4.2.5. Spain Market Size
9.4.2.5.1. Market Analysis
9.4.2.5.2. Emerging therapies analysis: Impact on the market
9.4.2.6. Italy Market Size
9.4.2.6.1. Market Analysis
9.4.2.6.2. Emerging therapies analysis: Impact on the market
9.4.3. Rest of Europe (ROE) Market Size
9.4.3.1. Assumptions
9.4.3.2. Market Analysis
9.4.3.3. Emerging therapies analysis: Impact on the market
9.4.4. Japan Market Size
9.4.4.1. Assumptions
9.4.4.2. Market Analysis
9.4.4.3. Emerging therapies analysis: Impact on the market
9.4.5. Rest of World (ROW) Market Size
9.4.5.1. Assumptions
9.4.5.2. Market Analysis
9.4.5.3. Emerging therapies analysis: Impact on the market

10. Market Drivers

11. Market Barriers

12. Report Methodology
12.1. Sources Used

13. Consulting Services

14. Disclaimer

15. About

List of Tables
Table 1: Total Prevalent Population of PAH in 7 MM (2016-2027)
Table 2: Prevalent Population of PAH in United States (2016-2027)
Table 3: Sub-type Specific Population of PAH in United States (2016-2027)
Table 4: Gender Specific Population of PAH in United States (2016-2027)
Table 5: Prevalent Population of PAH in Germany (2016-2027)
Table 6: Sub-type Specific Population of PAH in Germany (2016-2027)
Table 7: Gender Specific Population of PAH in Germany (2016-2027)
Table 8: Prevalent Population of PAH in France (2016-2027)
Table 9: Sub-type Specific Population of PAH in France (2016-2027)
Table 10: Gender Specific Population of PAH in France (2016-2027)
Table 11: Prevalent Population of PAH in Italy (2016-2027)
Table 12: Sub-type Specific Population of PAH in Italy (2016-2027)
Table 13: Gender Specific Population of PAH in Italy (2016-2027)
Table 14: Prevalent Population of PAH in Spain (2016-2027)
Table 15: Sub-type Specific Prevalent Population of PAH in Spain (2016-2027)
Table 16: Gender Specific Population of PAH in Spain (2016-2027)
Table 17: Prevalent Population of PAH in United Kingdom (2016-2027)
Table 18: Sub-type Specific Population of PAH in United Kingdom (2016-2027)
Table 19: Gender Specific Population of PAH in United Kingdom (2016-2027)
Table 20: Prevalent Population of PAH in Japan (2016-2027)
Table 21: Sub-type Specific Population of PAH in Japan (2016-2027)
Table 22: Gender Specific Population of PAH in Japan (2016-2027)
Table 23: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence
Table 24: Marketed Drugs developed by United Therapeutics Corporation
Table 25: Marketed Drugs developed by Actelion Pharmaceuticals Ltd.
Table 26: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences
Table 27: Marketed Drugs developed by Bayer (AG)
Table 28: Marketed Drugs developed by Pfizer
Table 29: Safety and Efficacy of Marketed Drugs
Table 30: Emerging therapies for the treatment of PAH
Table 31: Tysuberprost, Clinical Trials by Recruitment status, 2017
Table 32: Aurora GT, Clinical Trials by Recruitment status, 2017
Table 33: Macitentan: , Clinical Trials by Recruitment status, 2017
Table 34: Global Market Size of PAH in USD Million (2016-2027)
Table 35: 7 Major Market Size of PAH in USD Million (2016-2027)
Table 36: Market Size of PAH in United States, USD Million (2016-2027)
Table 37: Market Size of PAH in Germany, USD Million (2016-2027)
Table 38: Market Size of PAH in France, USD Million (2016-2027)
Table 39: Market Size of PAH in Italy, USD Million (2016-2027)
Table 40: Market Size of PAH in Spain, USD Million (2016-2027)
Table 41: Market Size of PAH in United Kingdom, USD Million (2016-2027)
Table 42: Market Size of PAH in Rest of Europe (ROE), USD Million (2016-2027)
Table 43: Market Size of PAH in Japan, USD Million (2016-2027)
Table 44: Market Size of PAH in Rest of World (ROW), USD Million (2016-2027)

List of Figures
Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
Figure 2: Functional Classification of PAH
Figure 3: Risk Factors of Pulmonary Arterial Hypertension
Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 6: Treatment Options for Pulmonary Arterial Hypertension (PAH)
Figure 7: Prevalent Population Of PAH in 7 MM (2016-2027)
Figure 8: Prevalent Population of PAH in United States (2016-2027)
Figure 9: Sub-type Specific Prevalent Population of PAH in United States (2016-2027)
Figure 10: Gender Specific Prevalent Population of PAH in United States (2016-2027)
Figure 11: Prevalent Population of PAH in Germany (2016-2027)
Figure 12: Sub-type Specific Prevalent Population of PAH in Germany (2016-2027)
Figure 13: Gender Specific Prevalent Population of PAH in Germany (2016-2027)
Figure 14: Prevalent Population of PAH in France (2016-2027)
Figure 15: Sub-type Specific Prevalent Population of PAH in France (2016-2027)
Figure 16: Gender Specific Prevalent Population of PAH in France (2016-2027)
Figure 17: Prevalent Population of PAH in Italy (2016-2027)
Figure 18: Sub-type Specific Prevalent Population of PAH in Italy (2016-2027)
Figure 19: Gender Specific Prevalent Population of PAH in Italy (2016-2027)
Figure 20: Prevalent Population of PAH in Spain (2016-2027)
Figure 21: Sub-type Specific Prevalent Population of PAH in Spain (2016-2027)
Figure 22: Gender Specific Prevalent Population of PAH in Spain (2016-2027)
Figure 23: Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 24: Sub-type Specific Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 25: Gender Specific Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 26: Prevalent Population of PAH in Japan (2016-2027)
Figure 27: Sub-type Specific Prevalent Population of PAH in Japan (2016-2027)
Figure 28: Gender Specific Prevalent Population of PAH in Japan (2016-2027)
Figure 29: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 30: Global Market Size of PAH in USD Million (2016-2027)
Figure 31: 7 Major Market size of PAH in USD Million (2016-2027)
Figure 32: Market Size of PAH in United States, USD Million (2016-2027)
Figure 33: Market Size of PAH in Germany, USD Million (2016-2027)
Figure 34: Market Size of PAH in France, USD Million (2016-2027)
Figure 35: Market Size of PAH in Italy, USD Million (2016-2027)
Figure 36: Market Size of PAH in Spain, USD Million (2016-2027)
Figure 37: Market Size of PAH in United Kingdom, USD Million (2016-2027)
Figure 38: Market Size of PAH in Rest of Europe (ROE), USD Million (2016-2027)
Figure 39: Market Size of PAH in Japan, USD Million (2016-2027)
Figure 40: Market Size of PAH in Rest of World (ROW), USD Million (2016-2027)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
  • Pfizer
  • United Therapeutics Corporation
  • others
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll